Tag Archives: National Institute of Allergy and Infectious Diseases

Research!America’s Inaugural Advocacy Academy

AAcademy1

Advocacy Academy participants: Mesias Pedroza, PhD, Baylor College of Medicine; Chloe N. Poston, PhD, Eli Lilly and Company; Jeffery G. Mellott, PhD Northeast Ohio Medical University

Last week, we held our inaugural Advocacy Academy, bringing 12 postdoctoral researchers from across the U.S. to Washington, D.C.  A two-day advocacy training program that culminated in Congressional visits with the participants’ representatives. We selected this group of motivated and concerned early-career scientists from a diversity of institutions, including Northeast Ohio Medical University, UCSF, Memorial Sloan-Kettering Cancer Center, Baylor College of Medicine, the University of Pennsylvania School of Nursing, Johns Hopkins University, Weill Cornell Medical College, the University of Washington and Banner Sun Health Research Institute, Eli Lilly and Company,  as well as local researchers at the National Cancer Institute and National Institute of Allergy and Infectious Diseases. For these young researchers, sequestration and budget cuts have clamped down on available resources to investigate diseases in the lab and raised concerns about the viability of a future career in research. Feeling compelled to take action, these postdoctoral research fellows came to Washington to convey the personal and societal importance of medical and health research.  And they did a terrific job. Continue reading →

Advertisements

Lancet Publishes Series on Drug-Resistant Tuberculosis

On March 24, World Tuberculosis Day, the Lancet published a series of papers on the need to combat drug-resistant tuberculosis. Cases of drug-resistant TB are on the rise, posing a growing threat to the health of populations in all parts of the world.

The series consists of six papers written by international experts in the tuberculosis field, including Professor Alimuddin Zumla, Director of the Centre for Infectious Diseases at the University College London Medical School and Dr. Marco Schito at the National Institute of Allergy and Infectious Diseases. Some papers focus on TB diagnostics, highlighting advances such as the Xpert MTB/RIF test as well as the dire need for new affordable and effective diagnostics that can detect drug-resistant strains of the disease. One paper focuses on the more technical aspects of the disease and identifies the need for additional funding to research biomarkers for drug-resistant TB. Yet another paper discusses the importance of integrated health service and control efforts, as countries are facing a high burden of TB as well as non-communicable diseases such as diabetes and cancer. Finally, the last two papers discuss the importance of community engagement in research and the need for visionary political leadership to advance global efforts to control TB.

Taken together, this series not only warns of the danger of the TB, but of the danger of inaction. If we are to make progress in the global fight against TB, we must take some of the recommendations for research and control efforts laid out in these papers. It will take concerted action from political leaders, health policy makers, funders and researchers to stem the growing threat of drug resistant TB.

-Morgan McCloskey, global health intern